Exploration and application of nanomedicine in atherosclerotic disease
Lobatto, M.E.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Chapter 8

Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis

Proceedings of the National Academy of Sciences USA 2014 Jan 21;111(3):1078-83


*= contributed equally to this work
Abstract

Therapeutic and diagnostic nanomaterials are being intensely studied for several diseases, including cancer and atherosclerosis. However, the exact mechanism by which nanomedicines accumulate at targeted sites remains a topic of investigation, especially in the context of atherosclerotic disease. Models to accurately predict transvascular permeation of nanomedicines are needed to aid in design optimization. Here we show that an endothelialized microchip with controllable permeability can be used to probe nanoparticle translocation across an endothelial cell layer. To validate our in vitro model, we studied nanoparticle translocation in an in vivo rabbit model of atherosclerosis using a variety of preclinical and clinical imaging methods. Our results reveal that the translocation of lipid–polymer hybrid nanoparticles across the atherosclerotic endothelium is dependent on microvascular permeability. These results were mimicked with our microfluidic chip, demonstrating the potential utility of the model system.
Introduction

Improving the design of nanomedicines is key for their success and ultimate clinical application\textsuperscript{1}. The accumulation of such therapeutic or diagnostic nanomaterials primarily relies on enhanced endothelial permeability of the microvasculature in diseased tissue\textsuperscript{2}. This holds true for a wide range of pathological conditions, including inflammation, atherosclerosis, and most notably, oncological disease\textsuperscript{3,5}. Although attributed to the enhanced permeability and retention (EPR) effect, the exact mechanism by which nanoparticles accumulate in tumors continues to be a topic of research\textsuperscript{7,8}. The “leaky” vasculature of tumors, which facilitates the extravasation of nanoparticles from microvessels\textsuperscript{9}, is a heterogeneous phenomenon that varies between different tumor models and even more so in patients. Moreover, the exploitation of nanomedicines in other conditions with enhanced microvessel permeability has only recently begun to be studied in detail. For example, in the last 5 y, a small but increasing number of preclinical studies that apply nanoparticle therapy in atherosclerosis models has surfaced\textsuperscript{10}. Although several targeting mechanisms have been proposed\textsuperscript{4}, the exact mechanism by which nanoparticles accumulate in atherosclerotic plaques remains to be investigated, but is likely facilitated by highly permeable neovessels that penetrate into the plaque from the vasa vasorum (Fig. 1A), a network of microvessels that supplies the wall of larger vessels\textsuperscript{11}.

Advances in biomedical imaging allow the study of plaque-targeting nanoparticles in a dynamic fashion with exceptional detail\textsuperscript{12,13}. Microchip technology has the potential to monitor nanoparticle behavior at the (sub)cellular level. Microfluidic chips in which endothelial cells (ECs) are grown in the channels can serve as unique in vitro test systems to study microvascular function and associated disorders\textsuperscript{14-18}. They allow the isolation of specific biological hallmarks relevant to nanoparticle accumulation, such as the leaky endothelium. In the current study, we validate the potential utility of our microchip technology to study nanoparticle translocation over the endothelium and combine this with in vivo and ex vivo multimodality imaging studies on a rabbit model to better understand nanoparticle targeting of atherosclerotic plaques.

Results and Discussion

We developed an endothelialized microfluidic device where the two-layer microfluidic channels are compartmentalized, which enables independent flow modulation in each channel and supply of controlled shear stress and stimuli to the cells (Fig. 1B)\textsuperscript{19}. To monitor permeability, we installed four electrodes into the inlet and outlet of the upper and lower channels and measured the transendothelial electrical resistance (TEER) across the endothelial layer (Fig. 1C; for details on device fabrication, see Materials and Methods and Fig. S1). Long-term culture of ECs with growth factors in the device produced a well-established endothelial monolayer with a TEER greater than 400 (Ω/cm\textsuperscript{2}) (Fig. 1D), which we independently corroborated with fluorescence microscopy (Fig. 1E). Systemic inflammation is known to play a pivotal role in endothelial dysfunction and the progression of atherosclerosis. Tumor necrosis factor α (TNF-α), an inflammatory cytokine with a wide range of proinflammatory activities, is involved in the pathogenesis of atherosclerosis and causes vascular dysfunction\textsuperscript{20}. Elevated levels of TNF-α in plasma are associated with cardiovascular risk\textsuperscript{21}. The plasma concentration of TNF-α in patients with coronary artery disease was found to be 21 ng/mL\textsuperscript{22}. When media with TNF-α (20 ng/mL) were infused into the microfluidic chip, this resulted in disrupted intercellular junctions (e.g., adherens junctions) and associated increased endothelial permeability (Fig. 1E). This was verified by increased translocation of FITC-labeled albumin, an endothelial permeability marker (Fig. 1F). We observed variations in TEER and albumin translocation under different cell culture media conditions (Fig. 1G). To study nanoparticle translocation, we designed and scaled up the production of a lipid–polymer hybrid nanoparticle that was labeled with gold nanocrystals (AuNCs) and the near infrared fluorescent (NIRF) dye Cy5.5 to allow its detection by transmission electron microscopy (TEM) and NIRF imaging, respectively (Fig. 1H and Fig. S2)\textsuperscript{23,24}.

Before nanoparticles were applied, we also studied the influence of shear stresses on endothelial permeability within the microfluidics device as hemodynamic forces can alter the function of ECs\textsuperscript{25}. Although shear stress (>15 dyne/cm\textsuperscript{2}) is a prerequisite to quiescent ECs and to align them in the direction of arterial blood flow, low shear stress (<4 dyne/cm\textsuperscript{2}) stimulates the development
of atherosclerosis. In our study, the endothelial monolayer showed a reduction in TEER (i.e., an increase in permeability) when cells were stimulated by shear stresses (1 and 10 dyne/cm²) (Fig. 2A). Additional stimulation with TNF-α (20 ng/mL) for 90 min led to a further increase in permeability, which could be altered by varying shear stress levels. The changes in permeability could be sustained for an additional 90 min, as indicated by the decreased TEER (Fig. 2B). After 90 min of TNF-α stimulation and another 90 min of relaxation, TEER remained stable for at least another 60 min (Fig. 2C). In addition, we note that the pressure differential across the endothelial layer in the chip can be modulated to, for example, mimic the high interstitial pressure of tumors.

Subsequently, we infused lipid–polymer hybrid nanoparticles in the device for 1 h and probed their translocation. The fluorescent intensity of the nanoparticles sampled from the lower channel every 10 min was ~4–5% of the initial intensity in the upper channel (Fig. 2D). Importantly, we found a significant increase of nanoparticle translocation across the endothelium when cells were treated with TNF-α and TEER decreased (Fig. 2E). Notably, a linear regression analysis showed a significant correlation (P<0.0001) between nanoparticle translocation and permeability as measured with TEER (Fig. 2F).

Figure 1. Development of an endothelialized microfluidic device to probe nanoparticle translocation over a permeable microvessel. (A) Schematics of continuous normal capillaries surrounding the vessel wall as well as permeable capillaries that penetrate into the atherosclerotic plaque from the vasa vasorum. (B) Schematic of an endothelialized microfluidic device that consists of two-layer microfluidic channels that are separated by a porous membrane (3 μm pore) on which ECs are grown. (C) TEER was dynamically measured across the endothelial layer on the membrane between the upper and lower channels. (D) A well-established monolayer of the microvascular endothelium is formed at TEER ~400 (Ω·cm²). (E) The monolayer becomes highly permeable when stimulated with the inflammatory mediator, TNF-α, as well as with shear stress, with disruption of intercellular junctional structures (i.e., adherens junctions) between ECs, as evidenced by patchy expression of VE–cadherin (green) in the image on the right versus the left. Blue depicts nuclei stained with DAPI. (Scale bar, 20 μm.) (F) FITC–albumin translocation through the endothelial monolayer increases when the chip is treated with TNF-α. (G) The chip with endothelium cultured in different culture media [base, +FBS, +growth factors (GFs)] for 6 h shows a decrease in TEER with increased FITC–albumin translocation. No cell indicates the membrane only. TEER was normalized to the level with no cells (membrane only). (H) Schematic and TEM image of PEGylated lipid-coated nanoparticles encapsulating PLGA-conjugated AuNCs and Cy5.5. The average size was 69.7 ± 14 nm, which was measured from TEM images. (Scale bar, 100 nm.) Details on labeling, synthesis, characterization, and large-scale production procedures can be found in Materials and Methods and Fig. S2.
To compare endothelial permeability of the endothelialized microfluidic chips with an in vivo atherosclerosis model, we used New Zealand White (NZW) rabbits that underwent a double balloon injury of the aorta and were fed a high-cholesterol diet, a well-established method to induce atherosclerotic lesions. These lesions have an abundance of neovessels that originate from the vasa vasorum within the adventitia of the vessel wall that can reach into the atherosclerotic plaque (Fig. S3). NZW rabbits that were fed a chow diet served as a healthy control group. We set up both in vivo and ex vivo imaging protocols (for details, see Materials and Methods) to investigate endothelial permeability of the entire aortic abdominal vessel wall. A 3D dynamic contrast enhanced magnetic resonance imaging (3D DCE-MRI) technique was used to probe atherosclerotic plaque microvessel permeability in vivo on a 3 tesla clinical MRI scanner. We observed a clear difference in vascular permeability between control and atherosclerotic rabbits (Fig. 3A), which is exemplified by the multiple red regions along the aorta of the atherosclerotic rabbit. We consequently validated the in vivo DCE-MRI results with ex vivo albumin-enhanced NIRF imaging of intact aortas. Similar to the experiments performed with the microfluidic device, albumin served as a tracer for vascular permeability. We observed a significant difference between the permeability of control and atherosclerotic aortas, confirming marked endothelial permeability in the atherosclerosis model (Fig 3B). Linear regression analysis showed a significant degree of correlation between the in vivo DCE-MRI and ex vivo permeability measures (Fig. 3C). To show the difference of the endothelial lining of the vessel wall at high resolution at microscopic levels, we performed TEM of ultrathin sliced sections (1 μm) of the excised aortas (Fig. 3D). The normal vessel wall was completely covered by an endothelial layer with tight interendothelial junctions, whereas the endothelial lining of the atherosclerotic vessel wall showed large paracellular gaps, which can potentially permit extravasation of macromolecules and cells.

Figure 2. Chip modulation, the monitoring of endothelial permeability, and nanoparticle translocation. (A) EC monolayers show an increase in permeability (i.e., a decrease in TEER) when ECs are exposed to shear stresses (1 and 10 dyne/cm²) for 24 h. (B) Stimulation with TNF-α (20 ng/mL) for 1.5 h leads to an increase in permeability (i.e., a decrease in TEER) for 3 h (with no treatment for 1.5 h). Lower shear stress shows the greatest increase in permeability in combination with TNF-α. TEER values are normalized at the beginning of TNF-α stimulation after 24 h of shear stress of 1 dyne/cm². The error bar is SEM (n = 3). (C) Variation of TEER over a 1 h time span, after 90 min of TNF-α stimulation followed by 90 min relaxation for 3 h in B. (D) Nanoparticle translocation is ∼4% after stimulation with TNF-α. For calculation of nanoparticle translocation, see Materials and Methods. (E) Stimulation with TNF-α, in addition to shear stress of 1 dyne/cm², increases nanoparticle translocation. The error bar is SD (n = 5). (F) Nanoparticle translocation and TEER are inversely correlated (r² = 0.54, P < 0.0001).
NIRF imaging was used to compare nanoparticle and albumin translocation in both the endothelialized microfluidic chip and the rabbit model of atherosclerosis. To this end, we prepared endothelialized microfluidic chips, subjected them to shear stress at 1 dyne/cm$^2$, and perfused them with either saline or TNF-α in pairs. Subsequently, the Cy5.5- and gold-labeled nanoparticles and Cy7-labeled albumin were perfused through the upper channel of the devices for 5 min, followed by a 1 min washing of the upper channel with culture media. The channels of both chips were imaged at 675–720 nm and 745–800 nm, to differentiate between Cy5.5 and Cy7, allowing quantification of both nanoparticle translocation and permeability (albumin). A significant difference in both nanoparticle translocation and permeability in the control versus the TNF-α-treated ECs in the chips was observed (Fig. 4A). Moreover, a significant correlation was found between nanoparticle translocation and permeability measured with Cy7–albumin (Fig. 4B). In addition, we injected healthy and atherosclerotic rabbits the same nanoparticles that were allowed to circulate for 1 h, after which rabbits were euthanized and aortas were harvested. A clear difference can be appreciated in nanoparticle uptake in the atherosclerotic aortas compared with the control aortas (Fig. 4C). Comparable to the microfluidic chips, a high degree of correlation was observed between nanoparticle translocation and microvessel permeability of aortas as determined by in vivo DCE-MRI and ex vivo NIRF imaging (Fig. 4D).
Figure 4. NlRF imaging of nanoparticle translocation in both microfluidic chips and rabbit aortas. (A) Microfluidic channels display pronounced translocation of both nanoparticles (Left) and albumin (permeability; Right) in the microfluidic channel treated with TNF-α in comparison with control (P<0.0001 and P=0.012). The experiments were performed in triplicate. (B) A high degree of correlation is measured between the translocation of nanoparticles and albumin in the endothelialized microfluidic channels (r²= 0.85, P<0.0001). (C) NlRF imaging of rabbit aortas injected with nanoparticles shows heterogeneous regions of nanoparticle uptake along the atherosclerotic aorta compared with control (both n=3, unpaired two-tailed t test, P<0.0001). (D) Correlation of nanoparticle and albumin translocation measured within rabbit aortas with NlRF imaging (r²=0.86, P<0.0001), as well as nanoparticle translocation compared with permeability measured with DCE-MRI (r²=0.63, P<0.0001).

We consequently looked at nanoparticle distribution at a cellular level with fluorescent microscopy of 5-μm-thick cross-sections. In control vessels, no fluorescent signal was observed, whereas the atherosclerotic vessel wall contained a substantial amount of nanoparticles within the atherosclerotic plaque, which was found at the luminal side of the plaque as well as near the vasa vasaorum (Fig. 5A). The incorporation of AuNCs also allowed nanoparticle visualization by TEM at subcellular resolution. Nanoparticle uptake related to endothelial permeability, as nanoparticles were found within vesicles of macrophages in proximity to endothelial gaps (Fig. 5B). In addition, a microvessel inside the plaque is shown, with a macrophage bordering the vessel that also contained nanoparticles.

Figure 5. Nanoparticle translocation within the atherosclerotic vessel wall. (A) Fluorescence microscopy images of typical cross-sections of the control and atherosclerotic vessel wall. No nanoparticles can be detected in the control vessel wall that has no atherosclerotic lesion (L, lumen), where the atherosclerotic vessel wall shows nanoparticle (red) translocation in the plaque (P). The FITC channel (green) was used to outline the vessel wall as it has autofluorescence in this range. (B) TEM at high resolution shows ECs with a gap between them and a macrophage (MΦ) behind it. At a higher magnification, multiple individual nanoparticles (arrowheads) can be found. (Scale bar, 2 μm.) The neovessel (N) within the plaque is bordered with a lipid-loaded MΦ that has taken up nanoparticles as well. (Scale bar, 1 μm.)
The microfluidic system presented here allows the study of nanoparticle translocation across the endothelium in a controlled fashion and therefore serves as a complementary in vitro model to screen nanoparticles and optimize their design. A limitation of the current study is that we did not screen for different particle sizes. Nevertheless, the translocation of the nanoparticle, which was of a therapeutically relevant size, correlated well with albumin-based permeability measures. Importantly, the same correlation between albumin deposition and nanoparticle accumulation was found in atherosclerotic aortas harvested from a rabbit model. An in-depth fluorescence and electron microscopy investigation revealed that these nanoparticles were deposited in vesicles of atherosclerotic plaque macrophages, in the proximity of disrupted endothelium, at both the luminal side of the plaque and microvessels in the adventitia that originate from the vasa vasorum.

The data demonstrate that nanoparticle translocation for plaque targeting occurs at sites of increased permeability, via the luminal and adventitial side of the arterial wall, providing good accessibility for nanomedicines to an atherosclerotic plaque. The integration of multimodality imaging revealed the similarities between the rabbit data and the in vitro model, which signifies that the microfluidic system can serve as a unique tool to examine nanoparticle translocation across microvessels. This integrative approach can be applied to optimize nanoparticle design and to study the potential of nanomedicine in the context of a range of other diseases, including cancer, diabetes, and inflammation.

## Materials and Methods

### Microfluidic Device Design and Fabrication.
The upper and lower channels were fabricated with polydimethylsiloxane (PDMS) (SYLGARD 184, Dow Corning) using standard soft-lithography techniques. The upper channel is 200 μm wide and 200 μm tall, and the lower channel is 400 μm wide and 200 μm tall. We installed the electrodes into the upper channel before bonding the two PDMS slabs with a microporous polyester membrane (CLS3452, Sigma-Aldrich) treated with 3-aminopropyl-triethoxysilane (APTES) to complete the device (Fig. S1).

**TEER Measurement.** We used commercially available voltmeters (EVOM, World Precision Instruments) to measure TEER. We optimized the length of the Ag/AgCl electrodes (381 μm in diameter, A-M Systems) to tune the base level resistance when they are embedded in microfluidic channels. We developed the custom connectors to fit both EVOM and our device. The unit of TEER was given by (Ohm·cm²) from TEER measurement (Ohm) and area of the membrane in the channel for better comparison.

### Cell Culture in the Chip.
Human umbilical vein ECs (HUVECs; PCS-100–013, ATCC) were maintained in vascular cell basal medium (VCBM; PCS-100–030, ATCC) supplemented with EC growth kit/VEGF (PCS-100–041, ATCC) at a pH of 7.4. The device, tubing, and other components were sterilized in 70% ethanol, washed with deionized (DI) water three times, rinsed with PBS three times, and dried in a sterilized area. The membrane was coated with 50 μg/mL fibronectin from human plasma (F2006, Sigma Aldrich) for 1 h. We infused 100 μL of HUVECs (>500,000 cells/mL) supplemented with EC basal medium (VCBM; PCS-100–030, ATCC) supplemented with EC growth kit/VEGF (PCS-100–041, ATCC) at a pH of 7.4. The device, tubing, and other components were sterilized in 70% ethanol, washed with deionized (DI) water three times, rinsed with PBS three times, and dried in a sterilized area. The membrane was coated with 50 μg/mL fibronectin from human plasma (F2006, Sigma Aldrich) for 1 h. We infused 100 μL of HUVECs (>500,000 cells/mL) into the microfluidic device and cultured them for 3–4 d.

### Shear Stress Calculation.
The volumetric flow rates of 0.8, 8, and 80 μL/min give 0.33, 3.3, and 33 mm/s of fluid velocity, where the shear stresses, \( \tau \), experienced by ECs were computed to be 0.1, 1, and 10 dyne/cm², respectively.

### Immunofluorescent Staining.
Cells were fixed with 2% paraformaldehyde, rinsed with PBS containing 1% BSA, permeabilized with 0.1% Triton X-100, and then immunostained with antibodies against vascular endothelial (VE)–cadherin (goat polyclonal IgG, 200 μg/mL, Santa Cruz Biotechnology) for 40 min at room temperature. Cultures incubated with goat IgG served as negative immunofluorescent controls. After washing, fluorescent secondary antibodies (Alexa-488–conjugated donkey anti-goat at 40 μg/mL, Invitrogen, Inc.) were added for 40 min in the dark at room temperature.

### FITC–Albumin Permeability Assay.
The endothelial permeability in the chip was also assessed by measuring FITC–albumin translocation across the monolayer. We infused 1 mg/mL of FITC–albumin in the medium into the upper channel at a flow rate of 8 μL/min, which corresponds to a shear stress of 1 dyne/cm². The translocation was determined by serially sampling the liquid continuously from the lower channel at a flow rate of 2 μL/min for 30 min.

### Nanoparticle Synthesis.
We prepared and synthesized AuNCs, PLGA-conjugated AuNCs, PLGA-conjugated Cy5.5 Rhodamine, Cy7-modified albumin, and lipid–PLGA nanoparticles (Fig. S2; for details on the nanoparticle synthesis, see Nanoparticle Preparation).

### Nanoparticle Suspension and Sampling.
Lipid–polymer nanoparticles (100 μg/mL) were suspended in medium and infused into the upper channel at a flow rate of 8 μL/min, which corresponds to a shear stress of 1 dyne/cm². The lower channel was serially sampled every 10 min at a flow rate of 2 μL/min for a total of 20 μL every 10 min for 1 h. Nanoparticle translocation (%) was calculated by the ratio of fluorescent intensity of sampled nanoparticles to fluorescent intensity of suspended nanoparticles. Fluorescent intensity of the nanoparticles was measured after nanoparticle solution was diluted; that is, 20 μL were diluted five times by adding 80 μL of medium to make the total volume of 100 μL.

### Animal Model.
Seven NZW male rabbits were included in this study. Four animals underwent a combination of a high-fat diet and balloon angioplasties to create advanced atherosclerotic lesions after a 6-mo time frame. A detailed account of the model has been described previously. Six animals underwent DCE-MRI (three control and three atherosclerotic animals). For DCE-MRI, animals were anesthetized with an intramuscular injection of Ketamine and Xylazine (35 mg/
kg and 5 mg/kg) and placed in the MRI under Isoflurane anesthesia at 1.5%, whereas vital parameters were monitored. Animals were killed by an overdose of 100 mg/kg sodium pentobarbital. All i.v. injections (Gadolinium, nanoparticles, Cy7–albumin, sodium pentobarbital) were administered through a 22 G catheter that was placed in the marginal ear vein. Before excision of the aortas, the rabbits were perfused with heparinized saline to clear the vasculature of blood. Aortas were measured in length, marked with sutures, and consequently harvested from the superior mesenteric artery to the iliac bifurcation. The complete excised vessel was imaged with NIRF imaging. All animal experiments were approved by the Institutional Animal Care and Use Committee at the Icahn School of Medicine at Mount Sinai.

### 3D DCE-MRI
A 3D DCE-MRI was performed on a 3T whole-body scanner (Philips Achieva) with a product 8 channels knee coil. The abdominal aorta was localized with scout scans and a time of flight noncontrast enhanced angiography. Gadolinium (gadopentetate dimeglumine, Magnevist, Bayer Healthcare) was injected during a 3D turbo field echo sequence with motion-sensitized driven equilibrium preparation for black blood imaging. The sequence covered the aorta from the right renal artery to the iliac bifurcation. Imaging parameters were set at the following: repetition time (TR), 6.2 ms; echo time (TE), 2.8 ms; flip angle, 20 degrees; echo train length (ETL), 80; spatial resolution, 0.6 mm³; field of view (FOV), 160 mm²; 20 slices; orientation, sagittal. Images were acquired before, during, and up to 10 min after contrast agent injection to quantify permeability of the vessel wall (acquisition with three signal averages; time resolution, 32 s).

### NIRF Imaging
A Xenogen IVIS-200 optical imaging system was used for NIRF imaging. Filters for imaging of the microfluidic device and imaging of excised aortas were set at 675–720 nm for detection of Cy5.5 and 745–800 nm for detection of Cy7. The exposure time for the microfluidic device was set at 40 s, binning at 4, and FOV of 6.5 cm. For the aortas, the exposure times were set at 5 and 2 s for Cy5.5 and Cy7 imaging, respectively, with binning at 4 and a FOV of 22.8 cm.

### Analyses of Imaging Data
In 3D DCE-MRI, the inner and outer walls of the aortas were traced on 162 ± 8 contiguous axially reformatted slices ranging from the left renal artery to the iliac bifurcation in OsiriX 5.6 (Pixmeo). The vessel wall contours were consequently superimposed to initial area under the curve (IAUC) parametric maps to calculate the under-the-contrast agent time curves for the average IAUC in the vessel wall of each traced axial slice. The IAUCs after 2 min were calculated with custom-built Matlab software and used as time point for data analysis. In the NIRF data analysis of the endothelialized microfluidic chips, six parallel regions of interest (ROIs) of 0.2 cm were placed, thereby covering the full channel. The ROIs were con- sequently copied and placed on the alternative wavelength. Total radiant efficiency [p/s]/[μW/cm²] was used for data analysis. For the excised aortas, ROIs of 1 cm were placed over the vessel wall, starting at the left renal artery down to the iliac bifurcation. According to aortic lengths, six or seven ROIs were placed. Similar to the microfluidic chips, the ROIs for one wavelength were transferred to the other. In the DCE analysis and DCE to NIRF image comparison, the IAUC 2 of the DCE data were divided into six or seven sections, according to the length of the aorta. The sum of the IAUC 2 in those regions was used for data analysis. Linear regression was calculated by matching the respective NIRF and DCE sections.

### Fluorescence Microscopy
After NIRF imaging, the part of the aorta below the left renal artery was transversely cut into 0.5 cm sections and embedded in optimal cutting temperature compound blocks and stored at −80 °C. The blocks were sectioned in 5 µm sections and mounted on slides with Vectamount (DAKO). Fluorescence microscopy was performed on a Zeiss Axioplan 2 microscope with a Cy5 filter for the detection of nanoparticles.

### TEM
TEM images were acquired using a Hitachi 7650 TEM operated at 80 kV coupled to a Scientific Instruments and Applications digital camera controlled by Maxim CCD software. For the nanoparticle imaging, the nanoparticle solution was negatively stained with a 2% phosphotungstic acid solution. Then, a 10 µL solution of nanoparticles was cast on a 100 mesh Formvar coated nickel grid (Electron Microscopy Sciences), air-dried, and imaged. For the animal model imaging, aortic rings of 0.5 cm were cut below the celiac artery immediately after sacrifice and stored in 3.0% glutaraldehyde in 0.2 M sodium cacodylate as a buffer in pH 7.4. The rings were washed in buffer and treated with osmium tetroxide 1% for 1 h and dehydrated in graded steps of ethanol, cleared with propylene oxide, and embedded in EMbed 812 (Electron Microscopy Sciences). Ultrathin sections were cut and mounted on a grid for imaging.

### Histology
Additional aortic rings were cut for conventional histology and placed in 4% paraformaldehyde. The rings were embedded in paraffin 24 h later and cut into sections of 5 μm thickness. CD-31 stain (Dako) for ECs was applied with methods described previously. Images were acquired with a Philips Digital Pathology scanner.

### Statistics
Paired t tests were used for the comparison of endothelialized microfluidic chips with optical imaging. Unpaired t tests were used for data analysis of the other microfluidic devices and analyses of the aortas. Linear regression was used for the correlative measures. Data are reported as mean ± SD. P values < 0.05 were considered statistically significant.
References

Acknowledgements

We thank the Institute for Electronics and Nanotechnology and the Petit Institute for Bioengineering and Bioscience at Georgia Institute of Technology. We thank the Microscopy Shared Resource Facility of Icahn School of Medicine at Mount Sinai for the use of fluorescent microscope, which is supported with funding from a National Institutes of Health (NIH)–National Cancer Institute shared resources grant (5R24 CA095823-04), a National Science Foundation Major Research Instrumentation grant (DBI-9724504), and an NIH shared instrumentation grant (1 S10 RR0 9145-01). This work was supported by the National Heart, Lung, and Blood Institute, NIH, as a Program of Excellence in Nanotechnology Award, Contract HHSN268201000045C (to Z.A.F. and R.L.); the National Cancer Institute Grant CA151884 (to R.L. and O.C.F.); the David H. Koch Prostate Cancer Foundation Award in Nanotherapeutics (to R.L. and O.C.F.); NIH Grants R01 EB009638 (to Z.A.F.) and R01CA155432 (to W.J.M.M.); a European Framework Program 7 Grant (to E.S.G.S.) (FP7-Health 309820: Nano-Athero); Netherlands Organization for Scientific Research ZonMW Vidi 91715324 (to W.J.M.M.); the Dutch Network for Nanotechnology NanoNext NL in the subprogram Drug Delivery; as well as the International Atherosclerosis Society and the Foundation “De Drie Lichten” in the Netherlands (to M.E.L.).

Supplementary information

Supporting information can be found online at http://www.pnas.org/content/111/3/1078.abstract?tab=ds.
**Supplementary figures**

**Fig. S1.** Microchip fabrication. The upper and lower channels were fabricated with Ag/AgCl nonpolarizable electrodes and a microporous polyester membrane cut from a Transwell insert (CLS3452, Sigma-Aldrich). To measure transendothelial electrical resistance (TEER), we designed custom electrical connectors using Ag/AgCl electrodes (381 μm in diameter, A-M Systems) to set base-level resistance across the upper and lower microfluidic channels. We used a commercially available voltohmmeter (EVOM, World Precision Instruments) to measure TEER from the electrodes embedded in the microfluidic chip. We optimized the length of the tubing enclosing the electrodes to have TEER measurable by EVOM as we found that the increase in the exposure area of the electrodes to the culture media can reduce TEER and its sensitivity in the confined microfluidic channels.

**Fig. S2.** Schematic description of the synthesis of PLGA functionalized with AuNCs. PLGA is modified at the carboxyl end with hydroxyl-modified AuNCs and then at the hydroxyl end with carboxyl-modified AuNCs via a Steglich esterification reaction. The same modification procedure was used for the synthesis of PLGA–Cy5.5 using carboxyl-modified Cy5.5.
Fig. S3. Immunohistochemistry of microvessels within atherosclerotic plaques with a CD-31 stain for endothelial cells. The color brown indicates a positive stain for endothelium. The lumen is lined with endothelium, with abundant microvessels in the adventitia as well as microvessels within the plaque. (Scale bars, 100 μm and 200 μm.)